Literature DB >> 34352610

Serum neurofilament is associated with motor function, cognitive decline and subclinical cardiac damage in advanced Parkinson's disease (MARK-PD).

Louisa Niemann1, Susanne Lezius2, Aleksandra Maceski3, David Leppert3, Catrin Englisch1, Edzard Schwedhelm4, Tanja Zeller5, Christian Gerloff1, Jens Kuhle6, Chi-Un Choe7.   

Abstract

INTRODUCTION: Serum neurofilament light chain (NfL) levels are associated with disease severity in early Parkinson's disease (PD). We assessed the association of serum NfL with motor and cognitive function and decline in advanced PD patients.
METHODS: NfL concentrations were analyzed with single molecule array (Simoa) assay in serum of 289 PD patients with advanced disease from the single-center prospective observational biobank study Biomarkers in Parkinson's disease (MARK-PD). Motor and cognitive symptoms were assessed with MDS-UPDRS III, Hoehn&Yahr stages and Montreal Cognitive Assessment (MoCA) at baseline and during 520 [364, 674] days of follow-up.
RESULTS: Serum NfL concentrations were associated with Hoehn&Yahr stages. During follow-up, baseline NfL levels were associated with time to cognitive decline in adjusted Cox regression models (hazard ratio: 3.23; 95% CI [1.16, 9.00], P < 0.025). Serum NfL was associated with NT-proBNP in adjusted models linking neuronal and cardiac damage in advanced PD patients.
CONCLUSION: In advanced PD patients, serum NfL concentrations are associated with motor function, cognitive decline and subclinical cardiac damage.
Copyright © 2021. Published by Elsevier Ltd.

Entities:  

Keywords:  Biomarker; Cognitive decline; Hoehn&Yahr; MOCA; NT-proBNP; UPDRS; motor decline

Mesh:

Substances:

Year:  2021        PMID: 34352610     DOI: 10.1016/j.parkreldis.2021.07.028

Source DB:  PubMed          Journal:  Parkinsonism Relat Disord        ISSN: 1353-8020            Impact factor:   4.891


  4 in total

1.  Reply to: "Age-Adjusted Serum Neurofilament Predicts Cognitive Decline in Parkinson's Disease (MARK-PD)".

Authors:  Whitley W Aamodt; Alice S Chen-Plotkin
Journal:  Mov Disord       Date:  2022-02       Impact factor: 10.338

2.  Neurological Involvement in COVID-19 Among Non-Hospitalized Adolescents and Young Adults.

Authors:  Lise Beier Havdal; Lise Lund Berven; Joel Selvakumar; Tonje Stiansen-Sonerud; Truls Michael Leegaard; Trygve Tjade; Henrik Zetterberg; Kaj Blennow; Vegard Bruun Bratholm Wyller
Journal:  Front Neurol       Date:  2022-06-22       Impact factor: 4.086

Review 3.  Blood-based biomarker in Parkinson's disease: potential for future applications in clinical research and practice.

Authors:  Lars Tönges; Carsten Buhmann; Stephan Klebe; Jochen Klucken; Eun Hae Kwon; Thomas Müller; David J Pedrosa; Nils Schröter; Peter Riederer; Paul Lingor
Journal:  J Neural Transm (Vienna)       Date:  2022-04-15       Impact factor: 3.850

4.  Association of admission serum levels of neurofilament light chain and in-hospital mortality in geriatric patients with COVID-19.

Authors:  Francesca Marchegiani; Rina Recchioni; Fiorella Marcheselli; Mirko Di Rosa; Jacopo Sabbatinelli; Giulia Matacchione; Angelica Giuliani; Deborah Ramini; Pierpaolo Stripoli; Leonardo Biscetti; Giuseppe Pelliccioni; Riccardo Sarzani; Francesco Spannella; Antonio Cherubini; Andrea Corsonello; Antonio Domenico Procopio; Anna Rita Bonfigli; Massimiliano Bonafè; Fabrizia Lattanzio; Fabiola Olivieri
Journal:  J Neurol       Date:  2022-09-16       Impact factor: 6.682

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.